Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

Systemic mastocytosis (SM) is a rare disease caused by an abnormal mast cell accumulation in various tissues. Two classes of constitutive activating c-kit mutations are found in SM. The most frequent class occurs in the catalytic pocket coding region with substitutions at codon 816 and the other in the intracellular juxtamembrane coding region. Therefore, kinase inhibitors that block mutated c-kit activity might be used as therapeutic agents in SM. Here, we show that STI571 inhibits both wild-type and juxtamembrane mutant c-kit kinase activity, but has no effect on the activity of the D816 V mutant. Accordingly, STI571 selectively decreases the survival of normal mast cell and of mast cell lines either with juxtamembrane c-kit mutations, but not that of tumoral mast cell from patient with SM or of mast cell lines with the D816 V mutation. Therefore, STI571 is not a good candidate to treat SM and specific kinase inhibitors should be designed to inhibit constitutive activating mutations at codon 816.

[1]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[2]  Yukihiko Kitamura,et al.  Decrease of mast cells in w/wv mice and their increase by bone marrow transplantation. , 1978 .

[3]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[4]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[5]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Duffy,et al.  The mast cell and mast cell disease. , 1995, Journal of the American Academy of Dermatology.

[7]  W. Vainchenker,et al.  Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7 , 2000, Leukemia.

[8]  T. Kaisho,et al.  Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. , 1999, Blood.

[9]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[10]  Y. Matsuzawa,et al.  Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.

[11]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[12]  A. Worobec.  Treatment of systemic mast cell disorders. , 2000, Hematology/oncology clinics of North America.

[13]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[14]  K. Zsebo,et al.  Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. , 1992, Blood.

[15]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[16]  M. Triggiani,et al.  Treatment of mastocytosis: pharmacologic basis and current concepts. , 2001, Leukemia research.

[17]  P. Valent,et al.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.

[18]  D. Birnbaum,et al.  Phosphatidylinositol-3′ Kinase Is Not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase* , 1996, The Journal of Biological Chemistry.

[19]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.

[20]  O. Hermine,et al.  TGF-beta1 drives and accelerates erythroid differentiation in the epo-dependent UT-7 cell line even in the absence of erythropoietin. , 2000, Experimental hematology.

[21]  B. Longley,et al.  A proposed classification of mastocytosis incorporating molecular genetics. , 2000, Hematology/oncology clinics of North America.